Submitted by moderna-user-01 on Tue, 12/13/2016 - 19:36
IND/CTA Filed: 
Yes
Phase 1: 
Phase 2: 
Phase 1 Text: 
Met 1°/2° endpoints
Lead: 
AstraZeneca
Phase 2 Text: 
Started: Jan '18
Target: 
VEGF-A
GLP Toxicology: 
Yes
Body: 

Modality:  Localized Therapeutics | Therapeutic Application:  Cardiovascular Disease (CV) and other ischemic vascular diseases

Partnered Program; Led by AstraZeneca

About The Program

mRNA AZD-8601 – VEGF-A: mRNA AZD-8601 is an investigational mRNA-based therapy being developed by AstraZeneca that encodes for vascular endothelial growth factor-A (VEGF-A). Using mRNA to initiate a strong, local and transient surge of VEGF-A expression could help overcome challenges associated with previous approaches to regulate this protein in tissues. When directed via local tissue injection, VEGF-A mRNA may potentially lead to the creation of more blood vessels and improved blood supply. mRNA AZD-8601 could one day provide a unique regenerative treatment option for patients with heart failure or after a heart attack, as well as for diabetic wound healing and other ischemic vascular diseases. 

Clinical Development

A Phase 1 safety study is currently enrolling patients in Europe. This study is a randomized, single-blind, placebo-controlled, single ascending dose study in male patients with Type 2 diabetes mellitus, performed at a single study center. This study is an essential first step to proving the clinical value of mRNA VEGF-A expression in cardiometabolic disease.

Formulation: 
Citrate/Saline